Nyxoah Announces Partnership with ResMed in Germany

Nyxoah Announces Partnership with ResMed in Germany
Creates a continuum of care in the German obstructive sleep apnea market

Mont-Saint-Guibert, Belgium – September 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has entered into a partnership with ResMed Germany to increase OSA awareness and therapy penetration in the German market.

Nyxoah and ResMed Germany will establish a continuum of care that will educate and guide OSA patients in the German market from diagnosis through treatment. Together, the companies will work to accelerate patient identification and better support patient set-up on the appropriate therapy. The companies will collaborate on:

  • OSA helplines and direct-to-consumer marketing initiatives
  • Sales and marketing efforts targeting ENTs and sleep physicians
  • Patient and clinician educational programs and symposiums

“We are thrilled to partner with ResMed Germany, as it strengthens further our patient-first approach to treating obstructive sleep apnea. OSA reduces quality of life and can result in other serious medical conditions, such as cardiovascular disease, and type 2 diabetes. Together, ResMed Germany and Nyxoah will heighten awareness of OSA and increase therapy penetration,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “The OSA ecosystem created by this partnership will guide patients from diagnosis to the right treatment for them, whether that is a mandibular device, continuous positive airway pressure (CPAP), or hypoglossal nerve stimulation (HGNS).”

'It is our joint goal to enable more patients to receive effective, personalized therapy,” said Katrin Pucknat, President, ResMed Germany. “Over 95 percent of patients in Germany suffering from sleep apnea are not diagnosed or treated. In addition, there are patients who have problems with their therapy and just stop it without considering an alternative. The partnership with Nyxoah will enable us to broaden the education around therapy options and empower patients to benefit from improved health outcomes.”

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313


Attachment

  • ENGLISH_Nyxoah - RMD Parternship


Nyxoah Announces Partnership with ResMed in Germany

THỦ THUẬT HAY

Kích hoạt thanh điều hướng ánh sáng trên Windows 10 Mobile

Trên Windows 10 Mobile chúng ta có một thanh kéo chỉnh độ sáng màn hình nhưng vì lý do gì đó mà một số dòng cũ lại không xuất hiện. Thật may mắn là chúng ta có thể đem thanh kéo này lên mọi dòng máy bằng cách tùy chỉnh

Hướng dẫn cài đặt và sử dụng phần mềm diệt virus Bkav Home

Nhờ trang bị công nghệ điện toán đám mây, liên tục cập nhật phiên bản mới, nâng cao khả năng diệt virus, ngăn chặn những mối đe doạ tiềm ẩn từ Internet kịp thời, đem lại sự an tâm cho người dùng mỗi khi lướt web. Bkav

Top những ứng dụng nên cài trên iPhone

Các ứng dụng luôn là một phần không thể thiếu đối với smartphone, cài những ứng dụng hữu ích sẽ góp phần làm tăng năng suất làm việc, bổ sung kiến thức hay thậm chí là tiết kiệm tiền bạc và thời gian cho người sử dụng.

Một vài mẹo hay dành cho Galaxy S9 mà bạn nên thử

Theo đó, Samsung họ tiết lộ rằng Galaxy S9 sẽ hỗ trợ xoay ngang tự nhiên trên giao diện trang chủ. Điều này cho phép người dùng sử dụng đa nhiệm một cách dễ dàng mà không cần xoay lại màn hình khi muốn mở ứng dụng

13 việc không nên làm khi sử dụng máy tính

PC cũng như mọi loại đồ điện tử khác cũng cần phải bảo trì, bảo dưỡng và cần sự quan tâm của người dùng trong suốt quá trình sử dụng. Thế nhưng nhiều người trong chúng ta lại mắc một số lỗi nên sự 'săn sóc' chưa tốt

ĐÁNH GIÁ NHANH

Cùng xem cuộc so găng giữa Canon 77D và Nikon D7500

77D – sản phẩm có số serie rất đặc biệt của Canon đang được đưa lên bàn cân để so sánh với chiếc máy mới ra mắt của Nikon là D7500. Xét về phân khúc thì cả hai đều thuộc dòng semi-pro trong khi thời gian ra mắt cũng

Phần cứng chiếc điện thoại Xiaomi Mi 6 có gì đặc biệt khiến bạn muốn mua ngay lập tức

Mi 6 có rất nhiều thứ mà những sản phẩm khác thèm muốn: phần cứng mạnh mẽ với chip Snapdragon 835, hai camera sau với zoom quang học 2x, và một thiết kế kim loại nguyên khối và kính tuyệt đẹp, với bán giá chỉ bằng một

Đánh giá Macbook Pro 2018: Liệu có xứng đáng để rút hầu bao?

Trước đó, Macbook Pro 2017 chỉ giống như một bản nâng cấp nhẹ của Macbook Pro 2016. Vì vậy, người dùng rất kỳ vọng bước nhảy vọt về hiệu suất trên Macbook Pro 2018.